Home › Postpartum Hemorrhage › NCT05245227
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
A Randomized Controlled Trial of Double Simultaneous Uterotonic Agents (Misoprostol Plus Intravenous Oxytocin) Versus Single Agent Regimen (Intravenous Oxytocin Only) to Prevent Early Postpartum Hemorrhage
Who can join
Ages 18 and older · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: \- All women 18 years and older admitted to delivery at Stony Brook University hospital who agree to participate in the study Exclusion Criteria: * Women under 18 years old * Women with known coagulation disorders * Women with planned cesarean hysterectomy * Women with known placental accreta spectrum disorders * Women with known allergy to prostaglandins
About the study
To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage.
There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage.
Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage.
Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).
What is being tested
- Sublingual Misoprostol (drug)
- IV Oxytocin (drug)
Sponsor: Stony Brook University · Participants: 1,358 · Started: Jan 27, 2025
Contact the study team
Official record on ClinicalTrials.gov — NCT05245227
Locations in the U.S.
| New York | Stony Brook University, Stony Brook |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.